Entries by Nascent

Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer

Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. Nascent CEO Sean Carrick stated, “On Friday December 7, 2018, Nascent Biotech received a letter from the FDA moving the Company’s IND filing from Full […]

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”. Click here to download the paper. Click here to download the supplementary information.

Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference

This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman. Click this link to download a PDF detailing the conference details, and how to register.

The Economist: Closing In On Cancer

The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect […]

Nascent Biotech Retires Liabilities with Non-Dilutive Funding

Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity. “With this funding we are now able to advance our asset through accelerated […]

Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China

Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA Public Company Information: OTC: NBIO Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., […]

Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors. Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting […]